PlasmaGen Biosciences, funded by Eight Roads, raises Rs 150 crore at a valuation of Rs 1,500 crore

PlasmaGen Biosciences has raised Rs 150 crore in a funding round led by ViNS Bioproducts, with participation from HNIs, family offices, pharma entrepreneurs, and existing investors. The Bengaluru-based startup was valued at over Rs 1,500 crore in the round.

Founded in 2010, PlasmaGen develops and manufactures blood plasma–derived therapies, including albumin, immunoglobulins, and anti-D products. The company supplies its products to private hospitals and state governments across India and has raised over Rs 600 crore in funding so far.

The fresh capital will be used to expand international operations, add new products, and strengthen manufacturing capacity and leadership teams. The fundraise follows the start of commercial operations in 2024 at PlasmaGen’s plasma fractionation facility in Kolar, near Bengaluru, which the company says is one of only five such facilities in India.

PlasmaGen reported strong revenue growth after starting operations at the Kolar plant and is now preparing to enter overseas markets. It has identified distribution partners in key export regions and is working on securing regulatory approvals for international sales.

India will continue to be a key market for the company, which is expanding its reach through a cold-chain-backed distribution network across hospitals and physicians.